Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. BiondVax Pharmaceuticals Ltd. (BVXV) Message Board

Study Links Gut Flora to Onset of Pediatric Rheuma

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 122
(Total Views: 149)
Posted On: 07/12/2023 5:27:18 PM
Avatar
Posted By: NetworkNewsWire
Study Links Gut Flora to Onset of Pediatric Rheumatism

The human body comprises many complex and interconnected systems that rely on and affect each other in myriad ways. One of the most complex systems is the gut biome, a collection of bacteria that live in the digestive tract and have a symbiotic relationship with humans.

The gut biome is made up of trillions of bacteria, fungi and viruses that aid digestion and affect immunity, brain and heart health. Researchers from the University of Florida and Linköping University have found that children who suffer from rheumatism exhibit differences in their gut biome compared to healthy children up to 10 years after infection.

The study is the first to link gut flora in early childhood with the development of pediatric rheumatism. It is the most prevalent joint inflammatory disease in children in the United States and currently has no cure.

Like all autoimmune conditions, pediatric rheumatism or juvenile rheumatoid arthritis occurs when the immune system mistakes healthy tissue as a danger and attacks, causing symptoms such as stiff, swollen and achy joints. Since pediatric rheumatism has no cure, children diagnosed with the condition usually have to take medication to suppress their immune systems for years, putting them at risk of developing other conditions.

Scientists across the world have spent years analyzing autoimmune conditions such as pediatric rheumatism to figure out their causes and develop effective cures and preventative measures. With the gut biome playing an important but often understated role in maintaining homeostasis or internal balance, researchers posited that it may play a role in the development of rheumatism in children.

Studies have found that the gut biome undergoes significant change during the first year of a baby’s life, with the composition of microorganisms in this ecosystem changing based on genetics, diet, infections and even bacterial antibiotics. The recent study looked at the composition of the gut biome alongside environmental and lifestyle factors several years before the development of pediatric rheumatism.

On average, some of the children who provided stool samples at around a year old were diagnosed with pediatric rheumatism three years later. Professor of Pediatrics at Linköping University and study colead Johnny Ludvigsson noted that individuals who later developed the autoimmune condition lacked some bacteria at one year of age. He added that courses of antibiotics could also potentially harm the gut biome and result in an imbalance while breastfeeding was associated with a decreased risk of developing pediatric rheumatism.

Proinflammatory bacteria such as Parabacteroides distasonsis also increased the risk of developing the condition while “good bacteria” such as Akkermansia were either limited or completely absent in children diagnosed with pediatric rheumatism.

As more companies such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) invest in developing immunotherapies for autoimmune illnesses, much more could be unearthed about how these conditions develop and manifest at a genetic or cellular level.

NOTE TO INVESTORS: The latest news and updates relating to BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are available in the company’s newsroom at https://ibn.fm/BVXV

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer





(0)
(0)




BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us